Spread of Psoriatic Disease from Skin to Joints

Save

Approximately 20 to 30 percent of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, psoriatic arthritis can lead to permanent damage to bones and joints.

Antirheumatic drug use with rheumatoid arthritis pregnancies

Save

A nationwide Norwegian registry study of rheumatoid arthritis (RA) pregnancies showed that while medication use increased during pregnancy, many discontinued treatment during pregnancy, only to resumed it after childbirth.

Nursing Shortage Could Worsen Due to Limited Student Loans

Save

In November, we reported on nursing groups that pushed back against a Trump administration proposal to de-list nursing as a professional degree for purposes of student borrowing. In this report, we look ahead to see what might happen as a result of the policy change.

Diffuse Alveolar Hemorrhage in Rheumatic Disease

Save

Subcutaneous Anifrolumab in SLE

Save

Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. 

2026 Resolutions (1.9.2026)

Save

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis

Save

Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA).

Subcutaneous Anifrolumab Effective in Lupus

Save

A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients living with moderate-to-severe systemic lupus erythematosus.

Glucocorticoid Injections in Knee Osteoarthritis

Save

A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).

Obesity and Low Back Pain

Save

A large patient population study finds weight gain,  increases risk for low back pain - the risk increased 7% for every BMI unit or 10 pounds over ideal weight. 

Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis

Save

Editor's note: This article was originally published April 22, 2025, and is being shared again as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!